Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness - Full Text View

Sponsor:	University of Medicine and Dentistry New Jersey
Collaborator:	National Institute on Drug Abuse (NIDA)
Information provided by:	University of Medicine and Dentistry New Jersey
ClinicalTrials.gov Identifier:	NCT00500695

Purpose

This project will assess the utility of a brief motivational intervention to engage smokers with schizophrenia in treatment for tobacco dependence treatment. It is hypothesized that a brief motivational intervention will be more effective in engaging smokers with schizophrenia to tobacco dependence treatment than an educational intervention. The educational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by teaching subjects about the negative effects of smoking and the success of tobacco dependence treatment. The motivational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by increasing subjects' motivation to change by presenting objective and personalized information regarding their smoking behaviors in a non-judgmental and supportive manner.

Condition	Intervention	Phase
Schizophrenia Schizoaffective Disorder	Behavioral: Motivational Interviewing or Psychoeducational Intervention	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

Resource links provided by NLM:

MedlinePlus related topics: Mental Disorders Schizophrenia Smoking

U.S. FDA Resources

Further study details as provided by University of Medicine and Dentistry New Jersey:

Primary Outcome Measures:

Attendance at first smoking cessation session [ Time Frame: one month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Cigarettes per day [ Time Frame: 1-Month Follow Up ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	May 2006
Estimated Study Completion Date:	October 2011
Estimated Primary Completion Date:	October 2011 (Final data collection date for primary outcome measure)

Intervention Details:

one-session, 45-minute behavioral intervention

Detailed Description:

See Brief Summary above.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Current smokers must be over the age of 18,
Must have a diagnosis of schizophrenia or schizoaffective disorder
Must smoke at least 10 cigarettes per day
Must be capable of giving informed consent as measured by Folstein Mini Mental Status Exam of at least 22

Exclusion Criteria:

•Those unable to give informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00500695

Locations

United States, New Jersey
UMDNJ- Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08901

Sponsors and Collaborators

University of Medicine and Dentistry New Jersey

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Marc L. Steinberg, PH.D.

University of Medicine and Dentistry New Jersey

More Information

No publications provided

Responsible Party:	Marc L. Steinberg, Ph.D., Assistant Professor, Robert Wood Johnson Medical School - UMDNJ
ClinicalTrials.gov Identifier:	NCT00500695 History of Changes
Other Study ID Numbers:	K23DA018203, K23DA018203
Study First Received:	July 12, 2007
Last Updated:	March 3, 2011
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Mental Disorders
Psychotic Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on February 09, 2012